FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Macias William L.					2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [ IMVT ]										Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner				
(Last) C/O IMMUNO	(First)	•	iddle)		3. Date of Earliest Transaction (Month/Day/Year) 01/11/2023									X	Officer (g below)	ve title Other (speci below) hief Medical Officer		specify	
320 W 37TH STREET, 6TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street) NEW YORK	NY	10	018									X Form filed by One Reporting Person  Form filed by More than One Reporting Person				g Person			
(City)	(State)	(Zi	p)																
1		Та	ble I - Nor	า-Deri	ivativ	e Se	curitie	s Acq	uired,	Disp	osed of,	or E	Benefi	cially Ow	ned				
Date					nsaction h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar				5. Amount Securities Beneficially Following I	y Owned Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	(Instr. 3 and 4)				(11150.4)
Common Stock <sup>(1)</sup> 01/1						11/2023			S		120		D	\$15.11(2)	307,981		D		
Common Stock <sup>(1)</sup> 01/1					11/2023				S		44,448		D	\$16.75(3)	263,533		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerci Expiration Da (Month/Day/Y		te Securitie		urities Un vative Se	derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio	e s lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
Explanation of Re					Code	v	(A) (D)		Date Exercisable		Expiration Date	Title		Amount or Number of Shares		(Instr. 4)	5.1(3)		

- 1. On November 5, 2021, the holder was granted 112,108 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 9, 2021. These RSUs vested in their entirety on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs and do not represent a discretionary sale by the holder.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.06 \$15.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.30 \$16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

## Remarks:

/s/ Eva Renee Barnett, attorney-in-01/13/2023 fact for William L. Macias

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.